Key result
Prasugrel monotherapy as an aspirin-free strategy for coronary intervention in diabetic patients is the focus of this editorial discussing the STOPDAPT-3 trial subanalysis.
Key points are not available for this paper at this time.
Design
Editorial
This is an editorial discussing the STOPDAPT-3 subanalysis on prasugrel monotherapy after PCI in patients with diabetes.
This editorial refers to, 'An aspirin-free strategy for percutaneous coronary intervention in patients with diabetes: a pre-specified subgroup analysis of the STOPDAPT-3 trial', by K. Yamamoto et al.
No takes yet. Share an insight, caveat, or question.
Kang et al. (2024) studied this question. Prasugrel monotherapy as an aspirin-free strategy for coronary intervention in diabetic patients is the focus of this editorial discussing the STOPDAPT-3 trial subanalysis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: